Tangram Therapeutics annonce le passage aux cohortes de patients dans l’essai de phase 1/2 RESTORE-MASH évaluant le TGM-312 et la nomination du Dr Sonya Montgomery au poste de directrice du développement

Phase 2TGM-312Positive

AI Analysis

Summary

Tangram Therapeutics announced advancement of TGM-312 to patient cohorts in the Phase 1/2 RESTORE-MASH trial and appointed Dr. Sonya Montgomery as Chief Development Officer to oversee clinical portfolio advancement.

Clinical Trial Data

Phase

1/2

Outcome Details

Progression to patient cohorts in Phase 1/2 RESTORE-MASH trial

Importance:5/10

Sentiment:

0.60

Phase_1/2Clinical_TrialRNAi_TherapeuticsMASHManagement_Appointment

Read the original article

Published by GlobeNewswire Clinical Studies on September 4, 2026 8:20 AM

Read Original